NCODA Logo

Daratumumab is an anti-CD38 monoclonal antibody (mAb) FDA approved for use in a range of multiple myeloma patients including first line, transplant-ineligible, and refractory.1 This PQI will provide guidance for optimal administration and management of both daratumumab infusions and subcutaneous formulation.